Showing results (301-310 of 777) with videos related to
Sort By:
Pageof 78
Immunotherapy|October 15, 2011
Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancerGüllü Görgün, Kenneth C AndersonBlood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.Blood|February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cellsYu-Tzu Tai, Ender Soydan, Weihua Song, et al.Science Advances|June 5, 2021
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironmentJiye Liu, Teru Hideshima, Lijie Xing, et al.Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.Blood|September 20, 2022
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growthEugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2009
Epigenetic modulation in hematologic malignancies: challenges and progressConstantine S Mitsiades, Kenneth C AndersonClinical Advances in Hematology & Oncology : H&O|November 1, 2005
Bortezomib: a novel therapy approved for multiple myelomaPaul G Richardson, Kenneth C AndersonOncotarget|September 20, 2012
Bruton's tyrosine kinase: oncotarget in myelomaYu-Tzu Tai, Kenneth C AndersonPageof 78